Belviq (Lorcaserin) is an anorectic medication manufactured by Arena Pharmaceuticals for the long-term management of obesity. As of 2012, the FDA approved lorcaserin to promote weight loss in adults with: BMIs exceeding 30 or BMIs exceeding 27 plus [at least] one weight-related medical comorbidity such as diabetes, hyperlipidemia, and/or hypertension. Upon administration, lorcaserin functions primarily …
Pindolol is a beta blocker initially synthesized by the pharmaceutical company Sandoz in the 1960s. As of 1977 it received FDA approval for the management of hypertension and was sold under the brand name “Visken.” Pharmacologically, pindolol acts as a non-selective beta blocker, meaning it competitively binds to all 3 beta-adrenergic receptor sites (Beta-1, Beta-2, …
Phentermine is a sympathomimetic amine [derived from amphetamine] initially approved by the FDA in 1959 for the treatment of obesity. Its usage in the treatment of obesity was considered ideal due to the fact that phentermine suppressed appetite through central modulation of norepinephrine, and peripherally mobilized fat stores through catecholaminergic upregulation. That said, in the …
Phentermine is an anorectic medication utilized principally for the short-term treatment of obesity as an adjunct to caloric restriction, dietary modifications, and physical exercise. It is formally classified as a psychostimulant due to the fact that it increases mental and physical arousal [via sympathomimetic mechanisms]. Specifically, phentermine facilitates central and peripheral catecholamine release (primarily of …
Phentermine is a natural monoamine alkaloid derivative that was initially approved by the United States FDA in 1959 as an anorectic (appetite suppressant) for the treatment of obesity. It was popularized throughout the early 1970s under the brand name medication “Fastin,” marketed by King Pharmaceuticals. In the late 1990s phentermine was discontinued from pharmaceutical circulation, …
Qsymia is a weight loss drug engineered by the California-based pharmaceutical company Vivus Inc. It was initially approved by the FDA in 2012 for weight reduction among adults with BMIs (body mass indexes) exceeding 30 kg/m² as an adjunct to interventions such as caloric restriction, dietary modification, and regular exercise. Qsymia is also approved for …
Naltrexone is a chemical initially synthesized in 1963 and patented thereafter by the pharmaceutical company Endo Laboratories in 1967. It is considered a substituted derivative of oxymorphone in that the tertiary amine methyl-constituent is replaced with an allyl group (specifically an N-cyclopropylmethyl group) – or a longer chain of carbon atoms. It was initially approved …